Monte Rosa Therapeutics, Inc..
GLUE.US | Research and experimental development on natural sciences and engineering
Monte Rosa Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel small molecule protein degraders. The company's proprietary QuEEN (Quaternary Encoding Enhanced Neomorph) platform is used to design and develop small molecule therapeutics that selectively degrade d...Show More
Better Health for All
0
Monte Rosa Therapeutics' entire business is devoted to discovering and developing novel small molecule protein degraders to treat serious diseases, including cancer, autoimmune, and inflammatory diseases. Its pipeline includes MRT-6160 in Phase 3 for immune-mediated diseases, MRT-2359 in Phase 1/2 for castration-resistant prostate cancer and HR+ breast cancer, and MRT-8102 in clinical development for inflammatory diseases.
1
The company has no revenue from products with negative health outcomes.
2
During the COVID-19 pandemic, the company modified its business practices in response to the crisis.
3
Monte Rosa Therapeutics holds pending and issued patents related to its QuEEN platform and product candidates, but explicitly states it does not offer expanded access to its investigational drugs outside of clinical trials.
4
The company references clinical trials, IRB approvals, and GCP compliance.
5
Fair Money & Economic Opportunity
0
Monte Rosa Therapeutics, Inc. is a biotechnology company focused on drug discovery and development.
1
The provided articles detail the company's financial results, research and development expenses, and clinical pipeline updates, including collaborations for drug development. As a biotechnology firm, its core business does not involve lending, deposit services, or other financial products for consumers. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value, which are designed to assess financial institutions, are not applicable to Monte Rosa Therapeutics' operations.
Fair Pay & Worker Respect
0
No evidence available to assess Monte Rosa Therapeutics, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Monte Rosa Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No specific, concrete evidence was found in the provided articles to assess Monte Rosa Therapeutics, Inc. against any of the 'Honest & Fair Business' KPIs. The articles either explicitly stated no relevant data, indicated unavailable URLs, or pertained to a different entity.
1
Kind to Animals
-50
Monte Rosa Therapeutics has 'Significant Involvement' in animal testing
1
, which is a required part of preclinical studies for FDA approval.
2
These nonclinical laboratory and animal tests must be conducted in accordance with Good Laboratory Practices (GLPs).
3
The company's policy articulates adherence to GLPs, which are legally mandated, but there is no evidence of a policy that goes beyond these basic regulatory requirements or sets measurable goals for reduction. While specific animal testing volumes are not provided,
4
the company's significant involvement in drug development, which inherently relies on animal testing, indicates a high volume of animals used without transparent reduction targets.
No War, No Weapons
0
No evidence available to assess Monte Rosa Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, factual evidence regarding Monte Rosa Therapeutics, Inc.'s performance on any of the Planet-Friendly Business KPIs was found in the provided articles. Both articles explicitly state that they contain no quantitative data, regulatory actions, certifications, awards, comparisons to industry benchmarks, or other relevant information pertaining to GLUE.US or the specified metrics.
1
Respect for Cultures & Communities
0
No evidence available to assess Monte Rosa Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No specific evidence regarding Monte Rosa Therapeutics, Inc. (GLUE.US) was found in the provided articles for any of the Safe & Smart Tech KPIs.
1
The articles discuss general cybersecurity and privacy issues within the healthcare sector but do not provide company-specific data, actions, or policies for GLUE.US.
2
Zero Waste & Sustainable Products
0
No specific, quantitative evidence was found in the provided articles to assess Monte Rosa Therapeutics, Inc. (GLUE.US) against any of the Key Performance Indicators for the 'Zero Waste & Sustainable Products' ethical value. The articles discuss general industry trends, challenges, and initiatives within the biotech and pharma sectors regarding waste reduction, packaging sustainability, and carbon emissions, but do not provide company-specific data for GLUE.US on any of the defined metrics.